Hot Features
Premium
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Amicus Therapeutics Inc | FOLD | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 10.82 | 03:29:31 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 10.82 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 9.70 - 14.57 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 10.82 | USD |
Amicus Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 3.2B | 295.38M | - | 399.36M | -151.58M | -0.51 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Amicus Therapeutics News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical FOLD Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 10.61 | 10.91 | 10.24 | 10.62 | 3,002,013 | 0.21 | 1.98% |
| 1 Month | 11.54 | 11.93 | 10.24 | 11.18 | 2,586,374 | -0.72 | -6.24% |
| 3 Months | 12.90 | 14.03 | 10.24 | 12.29 | 3,090,370 | -2.08 | -16.12% |
| 6 Months | 10.83 | 14.57 | 9.70 | 12.19 | 3,027,064 | -0.01 | -0.09% |
| 1 Year | 11.38 | 14.57 | 9.70 | 12.25 | 2,769,213 | -0.56 | -4.92% |
| 3 Years | 9.96 | 14.57 | 5.91 | 10.93 | 2,694,181 | 0.86 | 8.63% |
| 5 Years | 12.71 | 25.39 | 5.91 | 11.61 | 2,726,613 | -1.89 | -14.87% |
Amicus Therapeutics Description
| Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. |
